NCT06718894 Multitarget Strategy for Primary Podocytopathies
| NCT ID | NCT06718894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Condition | Nephrotic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-06-19 |
| Primary Completion | 2032-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-06-19 with a primary completion date of 2032-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder. Researchers will compare samples from patients with primary podocytopathies with those obtained from healthy subjects and patients with other renal disorders. Participants will be asked to visit the clinic at regular intervals for up to 36 months, and to provide blood and urine samples (and a sample of the discarded plasmapheresis effluent in case the procedure is performed).
Eligibility Criteria
Inclusion Criteria: * Signature of informed consent for study participation * One of the following conditions: 1. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant recurrence. 2. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant recurrence. 3. Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease. 4. Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition. 5. Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy). 6. Patients with no history of renal diseases Exclusion Criteria: * Subjects affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \< 15 ml/min) and/or on renal replacement therapy * Individuals unable to understand and consent to the study procedures * Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06718894 clinical trial?
This trial is open to participants of all sexes, studying Nephrotic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718894 currently recruiting?
Yes, NCT06718894 is actively recruiting participants. Contact the research team at manuel.podesta@policlinico.mi.it for enrollment information.
Where is the NCT06718894 trial being conducted?
This trial is being conducted at Milan, Italy, Pavia, Italy.
Who is sponsoring the NCT06718894 clinical trial?
NCT06718894 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 150 participants.